Info Diabetologie

, Volume 7, Issue 4, pp 28–36 | Cite as

Das Spektrum der Möglichkeiten wächst

Insulintherapie bei Typ-2-Diabetes heute
zertifizierte fortbildung

Zusammenfassung

Trotz verschiedener neuer Medikamente für Menschen mit Typ-2-Diabetes-mellitus wie den Inkretinmimetika hat die Insulintherapie nicht an Wichtigkeit eingebüßt. Im Gegenteil: Außer einer guten Schulung der Patienten, auch im Hinblick auf gesunde Ernährung, und der Blutzuckerselbstkontrolle ist die Insulintherapie ein essenzieller Baustein im sequenziellen Therapiekonzept von Menschen mit Typ-2-Diabetes [1].

Literatur

  1. 1.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012, 55(6):1577–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Holman RR, Farmer AJ, Davies MJ, et al. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009, 361(18):1736–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008, 371(9618):1073–84.PubMedCrossRefGoogle Scholar
  4. 4.
    Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011, 34(2):510–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract; 2011, 17(3):395–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Levin P, Wei W, Wang L, et al. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012; 28(3):439–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012; 14(4):304–14.PubMedCrossRefGoogle Scholar
  8. 8.
    Zeyfang A, Bahrmann A, Wernecke J. Diabetes mellitus im Alter. Die Praxisempfehlungen der DDG. Aktualisierte Version Diabetologie 2012; 7:S162–S169.Google Scholar
  9. 9.
    Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008; 51(3):408–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26(11):3080–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29(6):1269–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Siegmund T. Therapieregister Diabetes für die Klinik. Verlag Lehmanns Media, 1. Auflage Berlin 2011.Google Scholar
  13. 13.
    Lankisch MR, Ferlinz KC, Leahy JL, et al. Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008; 10(12):1178–85.PubMedGoogle Scholar
  14. 14.
    Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012, 8(12):728–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman-Levine JD, Patel DK, Schnee DM. Insulin degludec: a novel basal insulin analogue. Ann Pharmacother. 2013; 47(2):269–77.PubMedCrossRefGoogle Scholar
  16. 16.
    Pandyarajan V, Weiss MA. Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr Diab Rep. 2012, 12(6):697–704.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2013

Authors and Affiliations

  • Thorsten Siegmund
    • 1
    • 3
  • Petra-Maria Schumm-Draeger
    • 2
  1. 1.Städtisches Klinikum München GmbH, Klinikum BogenhausenMünchenDeutschland
  2. 2.Städtisches Klinikum München GmbH, Klinikum BogenhausenKlinik für Endokrinologie, Diabetologie und AngiologieMünchenDeutschland
  3. 3.Städtisches Klinikum München GmbH, Klinikum BogenhausenKlinik für Endokrinologie, Diabetologie und AngiologieMünchenDeutschland

Personalised recommendations